| 000 | 01778 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250514225835.0 | ||
| 264 | 0 | _c20050526 | |
| 008 | 200505s 0 0 eng d | ||
| 022 | _a1539-3704 | ||
| 024 | 7 |
_a10.7326/0003-4819-142-10-200505170-00007 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKanwal, Fasiha | |
| 245 | 0 | 0 |
_aTreatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. _h[electronic resource] |
| 260 |
_bAnnals of internal medicine _cMay 2005 |
||
| 300 |
_a821-31 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_aAdenine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aAntiviral Agents _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDecision Support Techniques |
| 650 | 0 | 4 |
_aHepatitis B e Antigens _xblood |
| 650 | 0 | 4 |
_aHepatitis B virus _ximmunology |
| 650 | 0 | 4 |
_aHepatitis B, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xeconomics |
| 650 | 0 | 4 |
_aLamivudine _xeconomics |
| 650 | 0 | 4 |
_aLiver _xenzymology |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 |
_aOrganophosphonates _xeconomics |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aSalvage Therapy |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 650 | 0 | 4 |
_aTransaminases _xblood |
| 700 | 1 | _aGralnek, Ian M | |
| 700 | 1 | _aMartin, Paul | |
| 700 | 1 | _aDulai, Gareth S | |
| 700 | 1 | _aFarid, Mary | |
| 700 | 1 | _aSpiegel, Brennan M R | |
| 773 | 0 |
_tAnnals of internal medicine _gvol. 142 _gno. 10 _gp. 821-31 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.7326/0003-4819-142-10-200505170-00007 _zAvailable from publisher's website |
| 999 |
_c15559867 _d15559867 |
||